Background-Bipolar disorder carries a substantive morbidity and mortality burden, particularly related to cardiovascular disease. Abnormalities in peripheral inflammatory markers, which have been commonly reported in case-control studies, potentially link these co-morbidities. However, it is not clear whether inflammatory markers change episodically in response to mood states or are indicative of chronic pro-inflammatory activity, regardless of mood, in bipolar disorder.
INTRODUCTION
Bipolar disorder is characterized by episodic fluctuations in mood, activity, and sleep typically lasting weeks to months and conveys a considerable morbidity and mortality burden. The disorder is also highly hereditable, yet there remains limited mechanistic insight into factors that contribute to its etiology and the pathogenesis of mood episodes. The most consistent neuroimaging finding in bipolar disorder involves a greater prevalence of white matter hyperintensities (WMH) on T2-weighted magnetic resonance images (Marlinge et al., 2014) . These WMH are seen 2.5 times as often as would be expected from healthy controls and it has been suggested that these lesions may occur secondary to inflammation (Ahn et al., 2004; Mahon et al., 2010) . Abnormalities in peripheral inflammatory markers with bipolar disorder have been commonly reported in case control studies (do Prado et al., 2013; Tsai et al., 2012) although it is not clear from these studies whether these markers change in response to mood state or are trait markers elevated in a subset of individuals with bipolar disorder.
In a meta-analysis of case-control studies of inflammation in bipolar disorder, including 761 cases and 919 healthy controls, those with bipolar disorder were found to have higher concentrations of soluble interleukin-2 receptor (sIL-2R), interleukin-6R receptor (sIL-6R), tumor necrosis factor alpha (TNF-α), soluble tumor necrosis factor receptor type 1 (sTNFR1), and interleukin-4 (IL-4) (Munkholm et al., 2013) . Of these cytokines, TNF-α has been studied the most and was associated with an effect size of 1.5 SD in the meta-analysis (Munkholm et al., 2013) . It was hypothesized that these findings are suggestive of a macrophage-T-lymphocyte process, involving the three macrophage derived cytokines (TNF-α, sTNFR1, sIL-6R) and T-cell derived sIL-2R. The majority of these studies, however, assumed trait differences in measures by simply comparing cases with bipolar disorder to controls. A few studies have assessed differences in inflammatory cytokines across mood states by either following participants from an acute mania to remission (Liu et al., 2004; Tsai et al., 2001) or comparing individuals with bipolar disorder who were euthymic to those in a mood episode (Barbosa et al., 2014; Brietzke et al., 2009; Cunha et al., 2008; De Berardis et al., 2008; Fontoura et al., 2012; Hope et al., 2011; O'Brien et al., 2006a; Ortiz-Dominguez et al., 2007; Tsai et al., 2012) . These studies identified a variety of differences in cytokines across mood states, generally suggestive of greater inflammation with abnormal mood states. The study of Barbosa et al. is an exception, which found no differences between mania and euthymia in levels of the only cytokines assessed, IL-33, and the soluble receptor through which it exerts its effects (Barbosa et al., 2014) .
In a sample of individuals with bipolar disorder and controls, we tested the hypothesis that TNF-α and macrophage-derived cytokines are elevated in bipolar disorder compared with controls and in the setting of acute mood episodes. We also sought to determine if any neuroimaging correlates of circulating cytokines could be identified by a novel whole-brain imaging technology, T1ρ, which is thought to be sensitive to pH and could potentially be influenced by focal areas of inflammation (Johnson et al., 2015a, b; Mangia et al., 2013) . In doing so, this is the first study of inflammation across distinct states of bipolar disorder to establish a sole primary hypothesis while simultaneously assessing patterns of inflammation across a variety of markers with neuroimaging correlates.
METHODS

Subjects
In total, 66 unique volunteers participated in this study, consisting of a group of 36 participants with a DSM-IV diagnosis of bipolar I disorder and a group of 30 healthy control participants, balanced for age and sex. Community diagnosis was confirmed by a one hour clinical interview with a study psychiatrist (JGF) using a template that specifically screened for tobacco, alcohol and drug use/abuse/dependence as well as common comorbidities such as psychosis, obsessions, compulsions, and panic attacks. Participants with bipolar I disorder were in either a manic episode (Young Mania Rating Scale (YMRS) ≥ 20), a depressive episode (Montgomery-Asberg Depression Rating Scale (MADRS) > 20), or a euthymic state (YMRS ≤ 12 and MADRS < 10) for the assessment. Healthy control participants had no history of psychiatric illness (either DSM-IV Axis I or Axis II). Participants were recruited through advertisements, referrals from the University of Iowa clinics and inpatient units, and a research registry. Participants were excluded if they had any history of brain damage, neurological problems such as seizure disorder, cardiac or respiratory diseases, alcohol or drug dependence, amphetamine use, or any contraindication to magnetic resonance imaging (MRI). Participants provided written informed consent for this study, which was approved by the University of Iowa Institutional Review Board.
Laboratory
Whole blood samples were obtained in the early afternoon and then, immediately following venipuncture, centrifuged at 4G for 12 minutes at which time plasma was extracted, Fiedorowicz et Based on prior evidence and/or preliminary data, the following inflammatory proteins were quantified using standard ELISA techniques (upper limit of detection): tumor necrosis factor-α (TNF-α, 7,500 pg/mL), soluble TNF receptor 1 and 2 (sTNF-R1, sTNF-R2, 6,250 pg/mL), Interleukin (IL)-1β (3,750 pg/mL), IL-1 receptor antagonist (IL-1RA, 3,000 pg/mL), IL-4 (3,750 pg/mL), IL-6 (3,750 pg/mL), IL-10 (7,500 pg/mL), IL-18 (16,875 pg/mL), IL-17, IL-18 binding protein (IL-18-BP, 180,000 pg/mL), interferon(IFN)-γ (3,750 pg/mL), monocyte chemotactic protein-1 (MCP-1, 3,750 pg/mL), fibroblast growth factor β (FGF-β, 5,000 pg/mL), transforming growth factor (TGF-β), brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF, 6,000 pg/mL). Values were truncated at the maximal value for any assay and values below the minimally detected threshold were recorded as zero. CRP was also assessed but results did not meet quality control standards and were subsequently not used in any analyses.
Imaging
Brain images were acquired using a 3 T Siemens Tim Trio MRI system (Magnetom; Siemens Healthcare, Erlangen, Germany) and a vendor-provided 12-channel receiver head coil. Anatomical T1-and T2-weighted images with 1.0 mm isotropic spatial resolution and a coronal whole-brain quantitative T1ρ map with 1.7×1.7×5.0 mm spatial resolution were acquired and processed using previously described methods (Johnson et al., 2015a) . Briefly, transformations were calculated to spatially align the anatomical images of the individual participants to a common brain atlas with brain tissue segmentation labels. (Halle et al., 2013) The transformations were then use to transform the T1ρ maps from the coordinate system of the individuals to the common coordinate system. Imaging transformations were made using a combination of BRAINS AutoWorkup (Pierson et al., 2011) , Advanced Normalization Tools (Avants et al., 2011) , and Analysis of Functional NeuroImages (Cox, 1996) . The T1ρ values, averaged over a given brain region, were extracted for use in subsequent analyses.
Data Analysis
Data analyses were conducted using SAS 9.4 (SAS Institute, Inc., Cary, NC). All statistical tests were two-tailed with an α=0.05. We primarily hypothesized the macrophage-derived TNF-α (sole a priori primary hypothesis) and secondarily hypothesized its soluble receptors (sTNF-R1, sTNF-R2), and other macrophage-derived cytokines (IL-1β, IL-6, IL-10, IL-18) would be elevated in bipolar disorder, particularly the abnormal mood states of mania and depression. Depression and mania groups were combined prior to any analyses because of the limited number of participants in these mood states and the existing literature outlining inflammatory perturbations in manic and depressive episodes. All other inflammatory proteins and related biomarkers were assessed in exploratory analyses. Univariate analyses compared concentrations of inflammatory proteins between diagnostic groups (bipolar disorder vs. healthy controls) as well as cases with abnormal mood states (i.e., mania and depression) and euthymia using the Wilcoxon Rank Sum test. Due to extreme skews of the laboratory data, variables were rank transformed for use in linear regression in models that adjusted for the potential confounding variables of age (linear effect), sex, smoking (dichotomous based on current use), and body mass index. To avoid over-fitting, medication use was subsequently controlled for in a sensitivity analysis by individually adding indicator variables for lithium, anticonvulsant, antipsychotic, antidepressant, and sedative/hypnotic use to the multivariate models. Regression diagnostics tested whether any statistical assumptions were violated.
To assess the potential role of changes in sleep with abnormal mood states on inflammatory and related biomarkers, we identified participants with reduced sleep based on a score of ≥2 on the YMRS or ≥3 on the MDRS sleep items as illustrated in Figure 1 . Given multicollinearity, the parameter estimates for reduced sleep were compared to parameter estimates for abnormal mood state in analogous models (not modeled simultaneously given collinearity) to determine whether the strength of the association was stronger or weaker.
Correlations were assessed between TNF-α and the average T1ρ signal bilaterally across specific brain regions of interest (i.e., amygdalae, hippocampus, and hypothalamus) as identified by the brain atlas segmentation labels (Halle et al., 2013) . The T1ρ within these three specific brain regions was hypothesized a priori to be correlated with specific inflammatory protein concentrations based on the extant literature identifying dysregulated processing of emotionally salient and stressful events as well as hypothesized sensitivity to cytokine-induced depression (Dantzer et al., 2008) and human evidence of neuro-immune interactions (Prossin et al., 2011; Prossin et al., 2015) . Exploratory analyses assessed correlations between other inflammatory proteins and these regions as well as two other specific regions of interest component to (or with significant projections to) cortico-limbic circuitry, the anterior cingulate and middle frontal gyrus.
RESULTS
The sociodemographic and clinical characteristics of the study sample are noted in Table 1 . Controls were significantly more educated than those with bipolar disorder and less likely to receive psychotropic medications. In linear regression models, those with mania had higher Young Mania Rating Scale (YMRS) scores (p<0.0001), higher Montgomery Asberg Depression Rating Scale (MADRS) scores (p<0.0001), and a marginally higher body mass index (BMI) (p=0.06) while those with depression had higher MADRS scores (p<0.0001) and a higher BMI (p=0.03). Smoking did not significantly differ across the four groups (p=0.18).
None of the 17 inflammatory proteins and related biomarkers were significantly elevated in cases with bipolar disorder relative to controls, when including those in euthymic states. As illustrated in In the sub-sample with available imaging (N=39), 21 controls and 18 with bipolar disorder, 8 of whom were in a euthymic state, 7 with mania, and 3 with depression), there was no correlation between TNF-α levels (rank-transformed) and average T1ρ signal across the amygdalae, hippocampi, and hypothalamus (Pearson r=0.048, p=0.77) . TNF-α levels were also not associated with T1ρ signal in the anterior cingulate gyrus (r=−0.080, p=0.63) or middle frontal gyrus (r=−0.14, p=0.40). In exploratory analyses assessing correlations involving the 16 remaining inflammatory proteins and T1ρ signals in five brain regions, there were no significant correlations apart from a single significant correlation between VEGF and T1ρ signal in the middle frontal gyrus (r=−0.34, p=0.03).
CONCLUSION
In this case-control study which sampled individuals with bipolar disorder in three distinct mood states, elevated inflammatory biomarkers were present in those with bipolar disorder in abnormal mood states, but not euthymia. The pattern of inflammatory activation, consistent with the prior literature and as subsequently hypothesized, appeared consistent with macrophage activation with marginal elevations in TNF-α, and significant elevations in its soluble receptors, IL-18, IL-18BP, and monocyte chemotactic protein-1. While the findings were strongest for these inflammatory biomarkers, specificity was limited as other inflammatory biomarkers were also elevated in those with abnormal mood states. Apart from a single, likely spurious, correlation, levels of inflammatory markers did not appear related to a novel imaging methodology, T1ρ, in the selected regions of interest. Perhaps other new imaging methods could be useful, such as positron emission tomography of translocator protein density in activated microglia as has recently been evidenced during major depressive episodes (Setiawan et al., 2015) .
Prior studies assessing inflammatory markers across mood states in bipolar disorder have either been exploratory in design or made corrections for multiple comparisons of up to 7 inflammatory markers, as illustrated in Table 4 (Bai et al., 2014; Barbosa et al., 2014; Cunha et al., 2008; De Berardis et al., 2008; Dickerson et al., 2007; Fontoura et al., 2012; Hope et al., 2011; Liu et al., 2004; O'Brien et al., 2006b; Ortiz-Dominguez et al., 2007; Tsai et al., 2012; Tsai et al., 2001) . Informed by these studies, our work identified a sole primary hypothesis for testing while assembling a panel of 17 makers to explore for potential patterns. Apart from two studies following inpatients with mania to remission (Liu et al., 2004; Tsai et al., 2001 ), studies of inflammatory involvement across mood states in bipolar disorder, including the current analysis, have not been prospective, rendering it difficult to discern whether any such changes persist beyond mood episodes and if so for how long and in what pattern. Consistent with our data, previous reports have shown that certain proinflammatory cytokines are not elevated during euthymia in research participants with a diagnosis of bipolar disorder (Guloksuz et al., 2010) . In a small prospective study, increased levels of IL-6 and IL-8 have been seen with mania (Munkholm et al., 2015) . Cross-sectional data from NHANES III, which assessed CRP as compared to time since last major depressive episode in participants with depression, suggest that CRP may remain elevated for 1-6 months beyond the last episode before normalizing (Danner et al., 2003) . If these findings are true for the cytokines assayed in the current analysis and in those with bipolar disorder, this could explain some of the inconsistencies in the existing literature. Several papers have reported higher levels of proinflammatory cytokines in those with bipolar I disorder during euthymic states (Barbosa et al., 2013a; do Prado et al., 2013; Modabbernia et al., 2013) and assessment of the duration of euthymia in future work may potentially add clarity to divergent findings. State-related inflammation changes may also explain the observed dose response between the persistence of mood symptoms, cardiovascular mortality and vascular dysfunction (Fiedorowicz, 2014; Fiedorowicz et al., 2012; Fiedorowicz et al., 2014; Fiedorowicz et al., 2009; Sodhi et al., 2012) .
The monocyte/macrophage pattern of immune activation observed in the current study is consistent with prior work (Munkholm et al., 2013) and may provide some clue to a biologically plausible potential pathway. Sympathetic nervous system (SNS) related patterns of immune response are designed to steer innate responses away from antiviral and toward natural (non-specific), proinflammatory responses (Irwin and Cole, 2011) . During fight-orflight responses, the SNS release of norepinephrine to primary and secondary lymphoid organs redeploys leukocytes and activates NF-κB-mediated pro-inflammatory responses (Irwin and Cole, 2011) . Mood states may hijack these pathways, which are evolutionarily conserved and designed to proactively protect organisms from risk of bacterial infection. This may maladaptively promote a variety of chronic diseases, including vascular disease, which accounts for considerable morbidity and mortality in bipolar disorder (Weiner et al., 2011) .
There exist certain limitations in the current study design. Diagnosis was confirmed on a clinical interview, rather than a structured interview, and may have missed some cooccurring psychiatric disorders. The cross-sectional nature of the data allows us to only infer that differences in cytokines are due to mood states. Prospective study is required to confirm that these cytokine levels acutely increase with onset of mood episodes. Based on the existing literature, which suggests overlapping patterns of inflammatory activation with these abnormal mood states (Barbosa et al., 2013b) and with a limited sample size, we grouped those with mania and depression for analyses. Such grouping does not allow us to differentiate any differences that may exist between these states, as have been shown for some, but not most, cytokines in other studies. This assumption would have been expected to, if anything, increase risk of type II error, particular with regard to any non-overlapping portions of cytokine activation. Multivariate models attempted to control for relevant confounding variables although some degree of residual confounding due undetected medical issues is possible. Our panel did not sample all cytokines, perhaps most notably Tcell derived sIL-2R, which has been significantly associated with bipolar disorder (Munkholm et al., 2013) . Our plasma assays are also unable to identify the source of cytokines. Cytokines such as TNF-α have been proposed to play a role as "neuromodulators in addition to inflammatory mediators" in the brain (Vitkovic et al., 2000) . The fact that T1ρ signal was not found to be correlated with cytokine levels in the selected regions of interest does not rule-out the possibility of brain involvement in neuroimmune interactions involved in mood disorders (Setiawan et al., 2015) . T1ρ is sensitive to increased free water and normal T1ρ suggests that measurable shifts or accumulation of free water (or swelling) that may derive from clinically relevant inflammation do not appear to be present.
Despite several case-control studies, little is known about whether pro-inflammatory states in bipolar disorder are a function of disease (trait), acute episodes (state), or both. The data we present identify the presence of "pro-inflammatory states" within those bipolar volunteers identifying signs/symptoms consistent with acute mood episodes. While this data suggests the presence of inflammatory activation within acute mood episodes, the crosssectional assessment limits the extent that such conclusions can be justified. A longitudinal study design that is capable of testing temporal variation within both healthy control individuals and bipolar individuals could differentiate between standard temporal/daily inflammatory variations (as have been reported) from true mood state variation in plasma inflammatory profiles. Future prospective study is also greatly needed to better discern the pattern of plasma inflammatory changes over time and their relation to mood state in this clinical group. Prospective study may also discern key mediators such as changes in sleep, the autonomic nervous system, or the hypothalamic-pituitary-adrenal axis. Future studies utilizing emerging neuro-imaging modalities that facilitate direct identification of neuroimmune interactions may be useful to understand any contribution of neuro-immune interactions to the episodic presentation of mood symptoms in bipolar disorder. Thresholds for Reduced Sleep. The dotted line illustrates the thresholds that were selected to identify individuals with reduced sleep, which involved a score of ≥2 on the YMRS sleep item or a score of ≥3 on the MADRS sleep item. Table 1 Sociodemographic and clinical characteristics of the sample. (13) 43 (13) 36 (13) 44 (13) 41 (14) Education, years ‡
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17 (2) 13 (2) 14 (2) 14 ( Table 3 Parameter estimates from regression models for abnormal mood state versus reduced sleep. Table 4 Studies of state related changes in inflammatory markers in persons with mood disorders. with euthymia, and 9 with depression) and 12 controls 1 inflammatory (several others for nitric oxide signaling and antioxidant activity) CRP elevated in mania compared with all other groups. Superoxide dismutase activity higher with mania.
Bonferroni correction for multiple comparisons.
Tsai SY et al., 2012 33 patients with bipolar I and mania (YMRS>26), some followed to partial or full remission, and 33 controls 3: hsCRP, IL-1RA, sTNF-R1 hsCRP higher for those in full remission than partial remission, but not mania. IL-1Ra higher with mania (marginally) and partial remission than full remission.
No primary hypothesis or control for multiple comparisons. The following studies were identified from systematic review of PubMed using search terms for major depression or bipolar disorder and inflammation (limit=human) and review of references from selected articles. Studies not designed to assess the impact of specific mood states in a mood disorder (e.g. no comparison to normal mood state in those with mood disorder) are not included. In the case of duplicate publications of the same sample, the most recent sample was selected. Those studies focused on changes in response to a particular treatment (e.g. lithium, sertraline) were also excluded. Abbreviations: CRP=C-reactive protein, HDRS=Hamilton Depression Rating Scale, hsCRP=highly sensitive CRP, IFN-γ=interferon gamma, IL=interleukin, IL-1RA=interleukin-1 receptor antagonist, MCP-1=monocyte chemotactic protein-1, OPG= osteoprotegerin, sCD4=soluble CD4, sCD8=soluble CD8, sIL-2R=soluble interleukin-2 receptors, sIL-6R=soluble interleukin-6 receptors, sPselectin=soluble P-selectin receptor, sST2=soluble receptor ST2, sTNF-R1=soluble tumor necrosis factor receptor 1, TNF-α=tumor necrosis factor alpha, vWF=von Willebrand factor, YMRS=Young
Mania Rating Scale
